Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?

Acta Neurologica Scandinavica

Volumn 122, Issue 5, 2010, Pages 309-315

  Elovaara, I ^a   Hietaharju, A ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adverse events; Cost Effectiveness; IVIG; Neurological diseases

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CXCL3 CHEMOKINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 4; PREDNISOLONE;

ANAPHYLAXIS; ATELECTASIS; AUTOIMMUNE DISEASE; BLOOD PRESSURE; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CUSHING SYNDROME; CYTOKINE PRODUCTION; DERMATOMYOSITIS; DRUG MECHANISM; DRUG MEGADOSE; DYSPNEA; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOMODULATION; LOW BACK PAIN; LYMPHOCYTE MIGRATION; MOLECULAR MECHANICS; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; OLIGODENDROGLIA; OPTIMAL DRUG DOSE; OSTEOPOROSIS; PATIENT SELECTION; PLASMAPHERESIS; PNEUMONIA; RELAPSE; REVIEW; SIDE EFFECT; STIFF MAN SYNDROME; T LYMPHOCYTE; TACHYCARDIA; THROMBOSIS;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; NERVOUS SYSTEM DISEASES; NEUROLOGY;

EID: 78649366873     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01317.x     Document Type: Review

References (58)

1. Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Pediatr Acta 1981;36:81-6.
2. Schmidt RE, Budde U, Schafer G, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet 1981;2:475.
3. Fateh-Moghadam A, Besinger U, Guersen RG. Ein klinisches Modell zur Regulation der Humoralen. Immunantwort: Infusion therapie. Beitr Infusionther. Klin Ernahr 1982;9:69-79.
4. Vermeulen M, Van Der Meché FGA, Speelman JD, et al. Plasma and gamma globulin infusion in chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1985;70:317-26.
5. Ceccarelli M, Pifferi M, Simoni F, Lupetti L, Ughi C. Initial experiences in the use of intravenous immunoglobulins in Guillain-Barré-Strohl syndrome. Pediatr Med Chir 1987;9:719-21.
6. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55.
7. Bayry J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol 2006;6:528-34.
8. Andersson U, Bjork L, Skansen SU, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994;139:21-42.
9. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997;126:721-30.
10. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006;313:670-3.
11. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939-50.
12. Van Schaik IN, Van Den Berg LH, De Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005;Apr 18;(2):CD004429.
13. Aktas O, Waiczies S, Grieger U, Wendling U, Zschenderlein R, Zipp F. Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis. J Neuroimmunol 2001;114:160-7.
14. Stangel M, Gold R. Intravenous immunoglobulins in MS. Int MS J 2005;12(1):5-10, 4.
15. Janke AD, Giuliani F, Yong VW. IVIg attenuates T cell-mediated killing of human neurons. J Neuroimmunol 2006;177:181-8.
16. Pigard N, Elovaara I, Kuusisto H, et al. Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression. J Neuroimmunol 2009;209:114-20.
17. Hughes RA, Raphaël JC, Swan AV, Van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2006;Jan 25;(1):CD002063.
18. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 2007;68:1144-6.
19. Eftimov F, Winer JB, Vermeulen M, De Haan R, Van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyneuropathy. Cochrane Database Syst Rev 2009;21:CD001797.
20. Hughes RAC, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-44.
21. Hughes RA. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial. Expert Rev Neurother 2009;9:789-95.
22. Elovaara I, Apostolski S, Van Doorn P, et al.(members of the EFNS task force). EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008;15:893-908.
23. Hughes RA, Swan AV, Van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004;Oct 18;(4):CD003280.
24. Léger JM, Viala K, Cancalon F, et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIG and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry 2008;79:93-6.
25. Terenghi F, Cappellari A, Bersano A, Carpo M, Barbieri S, Nobile-Orazio E. How long is IVIG effective in multifocal motor neuropathy? Neurology 2004;62:666-8.
26. Van Den Berg LH, Franssen H, Wokke JHJ. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 1998;121:421-8.
27. Piepers S, Van den Berg-Vos R, Van der Pol WL, Franssen H, Wokke J, Van den Berg L. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain 2007;130:2004-10.
28. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2006;Apr 19;(2):CD002277.
29. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis. A randomized controlled trial. Neurology 2007;68:837-41.
30. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007;21(Suppl. 1):S57-107.
31. Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol 2005;62:1689-93.
32. Fazekas F, Lublin FD, Li D, et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis. A dose-finding trial. Neurology 2008;71:265-71.
33. Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008;15:1163-7.
34. Achiron A. Winning combination: the additive/synergistic benefits of IVIg in corticosteroid refractory optic neuritis. Eur J Neurol 2008;15:1145.
35. Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004;364:1149-56.
36. Pöhlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 2007;13:1107-17.
37. Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 2004;61:1515-20.
38. Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler 2000;6(Suppl. 2):S18-20.
39. Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007;13:900-8.
40. Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 1996;243:25-8.
41. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
42. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term follow up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002;46:467-74.
43. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immunoglobulin for Stiff-person syndrome. N Engl J Med 2001;345:1870-6.
44. Gold R, Strangel M, Dalakas MC. Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007;3:36-44.
45. Tsai CP, Wang KC, Liu CY, Sheng WY, Lee TC. Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin. J Clin Neurosci 2007;14:625-9.
46. McCrone P, Chisholm D, Knapp M, et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2003;10:687-94.
47. Merkies LSJ, Bril V, Dalakas MC, et al. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%. The ICE study. Neurology 2009;72:1337-44.
48. RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009;8:158-64.
49. Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement by slow subcutaneous infusion. Ann Intern Med 1980;98:55-6.
50. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007;21:105-16.
51. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008;28:779-802.
52. Köller H, Schroeter M, Feischen H, Hartung HP, Kieseier BC. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 2006;253:1505-6.
53. Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008;37:406-9.
54. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 2009;16:631-8.
55. Eftimof F, Vermeulen M, De Haan RJ, Van Den Berg LH, Van Schaik IN. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 2009;14:93-100.
56. Dodel R, Hampel H, Depboylu C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Neurology 2002;52:253-6.
57. Solomon B. Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr Opin Mol Ther 2007;9:79-85.
58. Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;11:1728-36.